XWARSLV
Market cap212mUSD
Dec 20, Last price
47.25PLN
1D
-4.55%
1Q
-24.88%
IPO
121.83%
Name
Selvita SA
Chart & Performance
P/E
12.41
P/S
2.50
EPS
3.81
Div Yield, %
0.00%
Shrs. gr., 5y
2.66%
Rev. gr., 5y
37.47%
Revenues
347m
-14.85%
Net income
70m
+130.55%
CFO
79m
+4.71%
Profile
Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology, in vitro/ In Vivo pharmacology, ADME/DMPK and analytical testing. It also provides pharma services in the field of drug testing and bioanalytical analysis, including development and optimization, validation and transfer, stability studies, quality control, and regulatory aspects support services. In addition, the company offers research and development services in the areas of process research, laboratory scale custom synthesis of NCEs, industrial chemistry, and synthesis of isotopically labelled compounds, as well as other services for the agrochemical industry. Further, it provides bio-data science and advanced software services to data-driven life science and healthcare organizations. Selvita S.A. was founded in 2007 and is headquartered in Krakow, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 346,957 -14.85% | 407,462 31.05% | 310,921 126.36% | ||||||
Cost of revenue | 71,158 | 75,796 | 141,326 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 275,799 | 331,666 | 169,595 | ||||||
NOPBT Margin | 79.49% | 81.40% | 54.55% | ||||||
Operating Taxes | (2,675) | 7,599 | 2,846 | ||||||
Tax Rate | 2.29% | 1.68% | |||||||
NOPAT | 278,474 | 324,067 | 166,749 | ||||||
Net income | 69,878 130.55% | 30,309 103.43% | 14,899 -17.22% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 237 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 46,893 | 41,464 | 34,802 | ||||||
Long-term debt | 270,032 | 258,615 | 232,606 | ||||||
Deferred revenue | 33,011 | 11,020 | 2,043 | ||||||
Other long-term liabilities | 989 | 239 | 530 | ||||||
Net debt | 200,647 | 225,829 | 169,595 | ||||||
| Cash flow | |||||||||
Cash from operating activities | 78,980 | 75,430 | 87,472 | ||||||
CAPEX | (73,934) | (101,586) | (27,526) | ||||||
Cash from investing activities | (65,213) | (79,789) | (164,329) | ||||||
Cash from financing activities | (30,968) | (5,672) | 66,818 | ||||||
FCF | 222,751 | 191,905 | 77,348 | ||||||
| Balance | |||||||||
Cash | 52,965 | 76,175 | 96,984 | ||||||
Long term investments | 63,313 | (1,925) | 829 | ||||||
Excess cash | 98,930 | 53,877 | 82,267 | ||||||
Stockholders' equity | 240,623 | 186,713 | 119,107 | ||||||
Invested Capital | 486,886 | 441,015 | 293,343 | ||||||
ROIC | 60.02% | 88.26% | 79.22% | ||||||
ROCE | 46.79% | 66.17% | 43.13% | ||||||
| EV | |||||||||
Common stock shares outstanding | 18,355 | 18,355 | 18,355 | ||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | 321,251 | 368,494 | 197,083 | ||||||
EV/EBITDA | |||||||||
Interest | 11,826 | 4,196 | 3,801 | ||||||
Interest/NOPBT | 4.29% | 1.27% | 2.24% | ||||||